Caribou Biosciences Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
CRBU$0.41-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(113,615) | $(67,565) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,743 | 2,785 |
| Loss (gain) on disposal of fixed assets | 4 | (34) |
| Non-cash consideration for licensing and collaboration revenue | (1,634) | (61) |
| Change in fair value of equity securities | 116 | (3) |
| Stock-based compensation expense | 12,795 | 10,194 |
| Change in fair value of MSKCC success payments liability | (1,934) | (395) |
| Acquired in-process research and development | 1,625 | — |
| Accretion of discounts on investments in marketable securities, net | (3,708) | (6,042) |
| Non-cash lease expense | 1,690 | 1,551 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (36) | (931) |
| Contract assets | 628 | 588 |
| Other receivables | 603 | (130) |
| Prepaid expenses and other current assets | (428) | 852 |
| Other assets | (3,155) | (30) |
| Accounts payable | (125) | 1,089 |
| Accrued expenses and other current liabilities | 4,341 | 2,848 |
| Deferred revenue, current and long-term | (2,173) | (16,337) |
| Operating lease liabilities | (467) | (291) |
| Net cash used in operating activities | (102,730) | (71,912) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sales and maturities of marketable securities | 325,553 | 283,193 |
| Purchases of marketable securities | (248,889) | (310,566) |
| Purchases of property and equipment | (4,362) | (9,336) |
| Payments to acquire in-process research and development | (1,625) | — |
| Net cash provided by (used in) investing activities | 70,677 | (36,709) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from public follow-on public offering, net of offering expenses | — | 134,536 |
| Proceeds from issuances of common stock pursuant to private placement with Pfizer | — | 17,290 |
| Proceeds from exercises of stock options | 619 | 1,508 |
| Proceeds from issuances of common stock under ESPP | 913 | — |
| Proceeds from issuances of common stock related to our ATM, net of offering expenses | 11,329 | 1,007 |
| Net cash provided by financing activities | 12,861 | 154,341 |
| NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | (19,192) | 45,720 |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — BEGINNING OF PERIOD | 51,208 | 58,384 |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — END OF PERIOD | $32,016 | $104,104 |
| RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | ||
| Cash and cash equivalents | $31,970 | $104,058 |
| Restricted cash | 46 | 46 |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH ON THE BALANCE SHEET | $32,016 | $104,104 |
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||
| Cash paid for income taxes | $— | $170 |
| SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $373 | $556 |
| Offering costs included in accrued expenses | $— | $113 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.